摘要
目的:观察吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的疗效和毒性反应.方法:对28例NSCLC患者采用国产吉西他滨1000mg/m2,静脉注射30min,第1、8天,3~4周重复,2个周期后评价疗效.结果:28例均可评价疗效.总有效率(CR+PR)为30.6%(11/36),受益反应63.9%(23/36),毒副反应以骨髓抑制为常见.结论:吉西他滨单药治疗老年晚期NSCLC有较好疗效,毒性反应轻,患者易于耐受.
Objective:To evaluate the clinical effects and toxic reactions of gemcitabine monotherapy in the treatment of elderly patients with advanced non - small cell lung cancer (NSCLC). Methods:28 elderly patients with advanced NSCLC received gemcitabine 1000mg/m^2 intravenously on 1st and 8th day. The chemotherapy was repeated every 3 - 4 weeks. Curative effects and toxicities were evaluated after 2 cycles of chemotherapy. Results:The total effective rate was 30.6% (11/36). The beneficial response was 63.9% (23/36). The main toxicities were leucopenia and thrombocytopenia. Conclusion:Cemcitabine is effective, safe and well tolerable in the treatment of elderly patients with advanced NSCLC. It significantly improve the quality of life in patients with NSCLC and prolong their survival time.
出处
《内蒙古民族大学学报(自然科学版)》
2009年第2期208-209,共2页
Journal of Inner Mongolia Minzu University:Natural Sciences
关键词
非小细胞肺癌
化学治疗
吉西他滨
Non-small cell lung cancer (NSCLC)
Chemotherapy
Gemcitabine